Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
22 /100
LOW RISK
Score updated Aug 28, 2026

KROS — Keros Therapeutics, Inc. Dilution Risk Tracker

Track KROS dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track KROS — Get alerts when the score changes →

As of August 28, 2026, Keros Therapeutics, Inc. (KROS) has a DilutionWatch DilutionScore of 22/100, rated LOW dilution risk. Keros Therapeutics, Inc. has a market capitalization of $222.66M, 19.83M shares outstanding, 152 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
33
💰Cash Runway
📊 Float Risk
10
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for KROS.
🔔 Track KROS — Get forecast alerts →

Market Data

Market Cap$222.66M
Shares Outstanding19.83M
Float17.83M
Cash$257.61M
Debt$16.31M
Short InterestN/A

Institutional Holdings

QoQ: ↑ 2.8% shares (2026Q1 vs prior)
152 institutional holders · 21.90M shares
#1 BlackRock, Inc. 2.41M shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 1.66M shares
#3 Nantahala Capital Management, LLC 1.36M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest985.6K
Days to Cover5.9
% of Float5.5%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2020-12-31
4 INSIDER TRANSACTION 2026-03-11
4 INSIDER TRANSACTION 2026-03-11
3 FORM3 2026-03-11
4 INSIDER TRANSACTION 2026-02-26
Full SEC filing analysis available with free account

Recent News

No recent news

Factual KROS Dilution Snapshot

Keros Therapeutics, Inc. (KROS) has a DilutionScore of 22/100, rated Low dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track KROS Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking KROS — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for KROS
KROS FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.